CPRX CATALYST PHARMACEUTICALS, INC.
Q3 2025 10-Q
CATALYST PHARMACEUTICALS, INC. (CPRX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Management Discussion & Analysis
- • No quarterly revenue or YoY financial figures provided in text
- • No profitability or margin data included in MD&A section
Risk Factors
- • New risk: generic competition for FYCOMPA® tablets began entering market, threatening revenue and potential intangible asset impairment
- • Updated legal risk: ongoing litigation enforcement against Paragraph IV challenger seeking generic FIRDAPSE® entry intensified
Quarterly Financial SummaryXBRL
Revenue
$148M
▲ +15.3% YoY▲ +1.2% QoQ
Net Income
$53M
▲ +20.3% YoY▲ +1.3% QoQ
Operating Margin
44.7%
▲ +510bp YoY▼ -58bp QoQ
Net Margin
35.6%
▲ +147bp YoY▲ +2bp QoQ
ROE
5.7%
Total Assets
$1.1B
EPS (Diluted)
$0.41
▲ +17.1% YoY▼ 0.0% QoQ
Operating Cash Flow
$32M
▼ -55.5% YoY▼ -54.5% QoQ
Source: XBRL data from CATALYST PHARMACEUTICALS, INC. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on CATALYST PHARMACEUTICALS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.